Lavipharm SA reported consolidated and company earnings results for the first quarter ended March 31, 2012. For the quarter, on consolidated basis, the company reported operating revenues of EUR 10,005,000 compared to EUR 48,032,000 a year ago. LBIT was EUR 1,042,000 compared to EUR 486,000 a year ago. Loss before taxes was EUR 3,316,000 compared to EUR 3,078,000 a year ago. Loss after taxes distributed to shareholders was EUR 2,644,000 compared to EUR 2,317,000 a year ago. Total loss after taxes distributed to shareholders was EUR 2,069,000 compared to EUR 1,513,000 a year ago. Basic loss per share was EUR 0.0518 compared to EUR 0.0454 a year ago. LBITDA was EUR 164,000 compared to EBITDA of EUR 389,000 a year ago. Adjusted loss per share was EUR 0.0518 compared to EUR 0.0454 a year ago. Net cash flows provided by operating activities was EUR 13,028,000 compared to EUR 3,623,000 a year ago. Purchases of tangible and intangible assets were EUR 2,631,000 compared to EUR 95,000 a year ago. For the quarter, on company basis, the company reported operating revenues of EUR 10,463,000 compared to EUR 13,174,000 a year ago. EBIT was EUR 68,000 compared to LBIT of EUR 339,000 a year ago. Loss before taxes was EUR 463,000 compared to EUR 1,081,000 a year ago. Loss after taxes distributed to shareholders was EUR 471,000 compared to EUR 1,155,000 a year ago. Total loss after taxes distributed to shareholders was EUR 471,000 compared to EUR 1,155,000 a year ago. Basic loss per share was EUR 0.0092 compared to EUR 0.0226 a year ago. EBITDA was EUR 719,000 compared to EUR 325,000 a year ago. Adjusted loss per share was EUR 0.0092 compared to EUR 0.0226 a year ago. Net cash flows provided by operating activities was EUR 5,533,000 compared to EUR 1,633,000 a year ago. Purchases of tangible and intangible assets were EUR 2,548,000 compared to EUR 43,000 a year ago.